Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by:
University of Wuerzburg
ClinicalTrials.gov Identifier:
NCT00306813
First received: March 15, 2006
Last updated: August 3, 2009
Last verified: March 2006
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: December 2008
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):